Nebulized N-Acetyl Cysteine for Bronchiolitis in Inpatient Hospital Use

Nebulized N-Acetyl Cysteine for Bronchiolitis in Inpatient Hospital Use: A Randomized Controlled Trial

Bronchiolitis is the major cause of hospital admission in infants < 6 months of age and usually viruses like Respiratory syncytial virus (RSV), human metapneumo virus, Adeno virus, para-influenza virus, Rhino virus and influenza virus are the main culprit. In the US, acute bronchiolitis in infancy is responsible for approximately 150,000 hospitalizations yearly at an estimated cost of $500 million. Globally in 2005 it was estimated that at least 33.8 million were affected with RSV and in the same year, RSV associated severe acute lower respiratory infection (ALRI) were responsible for ~3.4 million hospitalizations and 66,000-199,000 deaths worldwide, with 99% of these deaths in developing countries.

In acute bronchiolitis there is cellular swelling and excessive mucus production. There is also proliferation of goblet cells, which leads to increased mucus production. The excess mucus produced is poorly cleared by non-ciliated (regenerating) epithelial cells leading to areas of narrowing and blocking of the bronchioles, causing the airway obstruction, hyperinflation, increased airway resistance, atelectasis and increased ventilation-perfusion mismatch that characterize acute bronchiolitis.

Currently there is no medicine that has proven effective in treating acute bronchiolitis and per American Academy of Pediatrics guidelines the management of acute bronchiolitis remains supportive care for the acute respiratory failure associated with acute bronchiolitis.

N-Acetyl Cysteine (NAC) is an antioxidant, anti-mucus compound that increases intracellular glutathione at the cellular level. It cleaves disulfide bonds by converting them to two sulfhydryl groups. This action results in the breakup of mucoproteins in lung mucus, reducing their chain lengths and thinning the mucus. Nebulized NAC is not studied well in acute bronchiolitis and is uncommonly used for the same. NAC has been studied in the treatment of various disease states, including those pulmonary in nature such as cystic fibrosis, chronic bronchitis, non-cystic fibrosis bronchiectasis and found to be beneficial.

With this background knowledge, the purpose of this study is to evaluate the effectiveness of nebulized mucolytic therapy in treatment of children with viral bronchiolitis.

Study Overview

• Status: Unknown
• Conditions: Bronchiolitis Acute
• Intervention / Treatment: Drug: N-Acetyl Cysteine

Detailed Description

A randomized clinical trial with blinding of person assigned for assessing and scoring the patients. The participants will include children less than 2 yrs. age admitted to the Pediatric Intensive Care Unit (PICU) with a diagnosis of acute bronchiolitis who will be randomized into either the NAC group or the non-NAC (Control) group.

Patients with acute bronchiolitis who require to be started on high flow nasal cannula support or any other noninvasive ventilator/BIPAP support are transferred/directly admitted to PICU. There is no time limit between when patients are admitted and when patients must sign consent or be randomized.

After a patient with acute bronchiolitis is identified, a member of the study team will perform a chart review to assess eligibility as described by the inclusion/exclusion criteria. If eligible, parent(s)/guardian(s) will be approached and Informed Consent will be obtained. Using randomization software(www.randomizer.org) the enrolled patients will be randomly assigned to either the NAC group or the non-NAC (Control) group.

The NAC will be ordered by the on call pharmacist and it will be administered by the on call Respiratory therapists. Between the two groups only the NAC group will get nebulized 2 ml of 10% NAC solution every 12 hours during their stay in PICU.

The PICU uses HHFNC (humidified high flow nasal canula), Heliox and non-invasive ventilation such as RAM canula, Neurally adjusted ventilatory assist (NAVA) and BIPAP. The PICU also typically uses Dexmedetomidine infusion once the patient is on non invasive ventilation (NIV) as a light sedation medication to avoid agitation and better ventilation patient synchrony.

The scoring tool used by Seattle children's Bronchiolitis pathway will be used. HHFNC (humidified high flow nasal cannula) will be started for patients when scores are ≥2. Depending on the clinical worsening the patient may require help with Heliox and escalation to non-invasive ventilation.

There will be twice a day blind assessments completed by experienced PICU/Transport nurses who were non-involved in patient care in PICU at that time. The pharmacist is going to use randomization software to randomly assign patients to a group (i.e control vs treatment). Also, the pharmacist will order code called as "Trial***" in the medical record (*** denotes a number assigned) and depending on the randomization the patient may or may not get the trial medication (Nebulized NAC). As such, all patients in the study will have a medical record orders which look similar to help achieve blinding at this stage for the treating physicians and independent evaluators.

All patients in the study will receive a type of respiratory support, such as High flow nasal cannula, noninvasive ventilator/ BIPAP etc. and because the NAC neb can easily be given through those circuits, no extra equipment will be required for patients who are in the treatment (NAC) group. Given that there is no difference in equipment in both treatment and control groups, the only way the double-blind is broken in this scenario is NAC's odor.

The odor of Neb NAC typically stays in the room during the treatment (2-3 minutes) and should not last >30 minutes after every administration. NAC is a sulfur compound and hence smells like "rotten eggs" so for precaution to maintain blindness, a respiratory therapist will spray a commercial rotten egg smelling solution at approximately the same time as treatment is administered for all patients in the study.

Because the NAC neb will be delivered through a closed respiratory circuit and also because the respiratory therapists use filters for nebulization treatments, the chances of sticky residues will be lower and hence difficult to figure out by examination.

The 12 hourly neb treatments will occur from 6:30-7:30am and pm respectively. This timing works in favor for blinding because both attending physicians and the independent evaluators are less likely to be present during this time. The assessment will involve scoring the patients according to the bronchiolitis scoring data tool. These assessments will be completed for the duration of the PICU stay. The on service PICU attendings will only be involved in clinical management of patients and will be blinded from randomization. The blinding will be broken if one of the on service physicians or PICU/Transport nurses performing assessments are aware of the currently admitted patient randomization details.

Reasons subjects may be withdrawn from the study: patient gets transferred to another facility due to family's requests, family wishes to withdraw in the middle of the study, or to protect the welfare of the patient.

• Study Type: Interventional
• Enrollment (Anticipated): 106
• Phase: Phase 4

Contacts and Locations

• Study Contact: Name: Rahul Pandey, MD; Phone Number: 9173745746; Email: rkpandey@carilionclinic.org
• Study Contact Backup: Name: Virginia Powel, MD; Email: vapowel@carilionclinic.org

Study Locations

• United States
  • Virginia
    • Roanoke, Virginia, United States, 24014
      • Recruiting
      • Carilion Clinic
      • Contact: Rahul Pandey, MD; Phone Number: 917-374-5746; Email: rkpandey@carilionclinic.org

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 1 year to 7 months (Child)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Full term new born neonates up to patients < 2yrs
• Respiratory score ≥2
• Otherwise healthy with new respiratory illness

Exclusion Criteria:

• Prematurity <34 weeks for patients <6 months age.
• h/o congenital heart disease requiring baseline medication
• Patient received diagnosis of Asthma or reactive airway disease in past.
• Anatomic airway defect.
• Immunodeficiency
• Chronic lung disease
• Patients who have had previous bronchiolitis < 4 weeks ago
• Patients intubated for acute bronchiolitis during the current admission.
• h/o Larynogomlacia, bronchomalacia or tracheomalacia.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Treatment Group; Subjects will receive N-Acetyl Cysteine (NAC) nebulized 2 mL of 10% NAC solution every 12 hours during their stay in the Pediatric Intensive Care Unit.	Drug: N-Acetyl Cysteine; Nebulized N-Acetyl Cysteine administered every 12 hours; Other Names: NAC
No Intervention: Control Group; Subjects will not receive NAC, but will receive standard care for acute bronchiolitis.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Respiratory Score	4 item scoring system completed by clinician used to assess respiratory symptoms. Each item is scored 0-3, with the value increasing as severity of symptoms increases.	1. Twice daily by physician 2. 15-30 min pre-treatment by nurse 3. 15-30 and 90 min post-treatment by nurse
Time on Non-Invasive Ventilation	Length of time on NIV	From time of PICU admission to time of PICU discharge, assessed up to 4 weeks
Duration of PICU/Hospital Admission	Length of time patient remains hospitalized	From time of hospital admission to time of hospital discharge, assessed up to 4 weeks

Collaborators and Investigators

• Sponsor: Carilion Clinic
• Investigators: Principal Investigator: Rahul Pandey, MD, Carilion Medical Center

Study record dates

Study Major Dates

• Study Start (Actual): February 1, 2018
• Primary Completion (Anticipated): May 31, 2020
• Study Completion (Anticipated): May 31, 2020

Study Registration Dates

• First Submitted: November 30, 2017
• First Submitted That Met QC Criteria: November 30, 2017
• First Posted (Actual): December 6, 2017

Study Record Updates

• Last Update Posted (Actual): September 26, 2019
• Last Update Submitted That Met QC Criteria: September 24, 2019
• Last Verified: September 1, 2019

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Lung Diseases; Bronchial Diseases; Lung Diseases, Obstructive; Bronchitis; Bronchiolitis; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Antiviral Agents; Protective Agents; Respiratory System Agents; Antioxidants; Antidotes; Free Radical Scavengers; Expectorants; Acetylcysteine; N-monoacetylcystine
• Other Study ID Numbers: IRB# 2314

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: Yes